Phospho-PXN (Tyr88) Antibody

What is Phospho-PXN (Tyr88) antibody and what does it detect?

Phospho-PXN (Tyr88) antibody is a polyclonal antibody that specifically recognizes paxillin protein only when phosphorylated at tyrosine 88 (Y88). This antibody detects endogenous levels of paxillin with this specific post-translational modification, allowing researchers to study the phosphorylation state of this key cytoskeletal protein. The antibody is typically generated by immunizing rabbits with synthetic phosphopeptides derived from the region surrounding the phospho-tyrosine 88 residue of human paxillin . Non-phospho specific antibodies are typically removed during purification through chromatography to ensure specificity for the phosphorylated form .

What is the significance of paxillin and its phosphorylation at Tyr88 in cellular processes?

Paxillin is a 68 kDa cytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix, specifically at focal adhesions. It functions as a molecular scaffold recruiting various proteins to these sites. Phosphorylation at Tyr88 represents a specific regulatory mechanism that modulates paxillin's function in cell adhesion, migration, and signal transduction pathways . This phosphorylation event is particularly relevant in understanding cellular processes such as cell motility, adhesion dynamics, and signal transduction through focal adhesion complexes. Paxillin recruits other proteins such as TRIM15 to focal adhesions and colocalizes with integrins at the cell periphery and with membrane ruffles at the leading edge of migrating cells .

What applications is Phospho-PXN (Tyr88) antibody suitable for?

Phospho-PXN (Tyr88) antibody is validated for multiple research applications:

These applications allow researchers to study paxillin phosphorylation in various experimental contexts, from protein expression levels to subcellular localization patterns .

How should I optimize Western blot protocols when using Phospho-PXN (Tyr88) antibody?

For optimal Western blot results with Phospho-PXN (Tyr88) antibody, incorporate these methodological considerations:

• Sample preparation: Use phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in your lysis buffer to preserve phosphorylation status.

• Protein loading: Load 20-50 μg of total protein per lane, depending on expression level in your samples.

• Blocking: Use 5% BSA in TBST rather than milk, as milk contains phosphoproteins that may interfere with detection.

• Antibody dilution: Start with 1:1000 dilution in 5% BSA/TBST and optimize if needed.

• Controls: Include both phosphatase-treated samples as negative controls and samples from cells treated with pervanadate (phosphatase inhibitor) as positive controls.

• Membrane washing: Perform stringent washing steps (at least 3×10 minutes with TBST) to reduce background.

• Signal detection: Use enhanced chemiluminescence systems optimized for phosphoprotein detection .

Following these steps helps ensure specific detection of phosphorylated paxillin while minimizing background interference.

How can I validate the specificity of Phospho-PXN (Tyr88) antibody in my experimental system?

Validating antibody specificity is crucial for reliable research outcomes. For Phospho-PXN (Tyr88) antibody, implement the following validation approach:

• Alkaline phosphatase (AP) treatment: Treat half of your sample with AP to remove phosphate groups. The signal should disappear in AP-treated samples if the antibody is truly phospho-specific .

• Peptide competition assay: Pre-incubate the antibody with phospho-peptide immunogen to block specific binding sites. Signal reduction indicates specificity.

• Tyrosine kinase inhibition/activation: Treat cells with appropriate inhibitors or activators known to affect paxillin phosphorylation. For example, use EGF stimulation as a positive control .

• Knockout/knockdown controls: Use paxillin-deficient samples as negative controls.

• Cross-reactivity assessment: Test the antibody on samples from different species to confirm its reactivity profile matches manufacturer claims .

These validation steps collectively strengthen the reliability of your phospho-paxillin detection methodology.

How can I incorporate Phospho-PXN (Tyr88) antibody into quantitative phosphoproteomics workflows?

Integrating Phospho-PXN (Tyr88) antibody into phosphoproteomics requires specialized approaches:

• Reverse Phase Protein Array (RPPA): This high-throughput method allows quantitative profiling of phosphorylation events across multiple samples. For Phospho-PXN (Tyr88), use a lysis buffer compatible with alkaline phosphatase treatment for validation controls. RPPA has demonstrated reproducibility and specificity for clinical specimens, including both fresh frozen and FFPE tissues .

• Immunoaffinity purification coupled with mass spectrometry:

  • Enrich phosphotyrosine peptides using Phospho-PXN (Tyr88) antibody-based immunoprecipitation

  • Combine with stable isotope dimethyl labeling prior to immunoaffinity purification

  • This approach enables quantification of tyrosine phosphorylation differences under various conditions (e.g., growth factor stimulation)

  • For optimization, start with approximately 4 mg of protein material to achieve sufficient enrichment

• Multiplexed antibody-based assays: Incorporate Phospho-PXN (Tyr88) antibody alongside other phospho-specific antibodies in multiplexed detection platforms for pathway analysis.

With these approaches, researchers can achieve comprehensive quantitative profiling of paxillin phosphorylation status across experimental conditions.

What are the most effective strategies for studying temporal dynamics of paxillin Tyr88 phosphorylation in living cells?

For investigating dynamic phosphorylation events:

• Time-course immunofluorescence: Fix cells at different time points after stimulation (e.g., EGF treatment, integrin engagement) and perform immunofluorescence with Phospho-PXN (Tyr88) antibody. Use confocal microscopy with appropriate co-staining markers for focal adhesions.

• Phosphorylation kinetics monitoring:

  • Treat cells with stimuli known to induce paxillin phosphorylation

  • Harvest cells at multiple time points (e.g., 0, 5, 15, 30, 60 min)

  • Process for Western blot analysis with Phospho-PXN (Tyr88) antibody

  • Normalize phospho-signal to total paxillin levels using a non-phospho-specific paxillin antibody

• FRET-based biosensors: While not directly using the antibody, designing FRET biosensors based on the epitope recognized by Phospho-PXN (Tyr88) antibody can provide real-time visualization of phosphorylation events.

• Correlation with focal adhesion dynamics: Combine Phospho-PXN (Tyr88) immunostaining with live-cell imaging data of focal adhesion proteins to correlate phosphorylation with adhesion assembly/disassembly events .

These methods provide complementary information about the spatiotemporal regulation of paxillin phosphorylation in cellular contexts.

How should I troubleshoot inconsistent results when using Phospho-PXN (Tyr88) antibody in different experimental systems?

When encountering variability across experiments:

• Sample preservation: Phosphorylation status can rapidly change during sample processing. Ensure immediate sample denaturation in hot SDS-PAGE buffer or flash-freezing in liquid nitrogen.

• Storage conditions: Store the antibody at -20°C and avoid repeated freeze/thaw cycles. Aliquot the antibody upon first use to maintain consistent performance .

• Epitope accessibility: For fixed samples, optimize fixation conditions (type, duration, temperature) as over-fixation may mask the phospho-epitope.

• Cross-reactivity assessment: If working with non-human samples, validate antibody specificity in your specific species, as the phosphorylation site might not be conserved.

• Cell culture conditions: Standardize culture conditions, as serum factors, cell density, and stress can significantly affect baseline phosphorylation levels.

• Sample processing standardization: Use a standard protocol for sample collection, lysis, and processing to minimize technical variability between experiments.

• Biological variability consideration: Account for inherent biological variability by increasing biological replicates and using appropriate statistical analyses.

Implementing these troubleshooting approaches helps achieve more consistent and reliable results when working with phospho-specific antibodies .

How can Phospho-PXN (Tyr88) antibody be utilized in cancer research models?

Phospho-PXN (Tyr88) antibody offers valuable applications in cancer research:

• Biomarker identification: Paxillin phosphorylation status can serve as a potential biomarker for cancer progression and metastatic potential. Using Phospho-PXN (Tyr88) antibody in RPPA or immunohistochemistry workflows allows screening of large sample cohorts for correlation with clinical outcomes .

• Cell migration and invasion studies:

  • Assess paxillin phosphorylation at Tyr88 in relation to cancer cell migration capabilities

  • Compare phosphorylation patterns between primary and metastatic cell lines

  • Evaluate effects of therapeutic compounds on paxillin phosphorylation and subsequent migration

• Signaling pathway analysis: Integrate paxillin Tyr88 phosphorylation data with other phosphoprotein measurements to map cancer-specific signaling networks.

• Therapeutic response monitoring: Track changes in paxillin phosphorylation during treatment with kinase inhibitors or cytoskeletal-targeting agents to assess molecular response .

These approaches contribute to understanding the role of focal adhesion dynamics and cytoskeletal reorganization in cancer progression and metastasis.

What methodological adaptations are necessary when analyzing phospho-paxillin in different tissue preparation formats?

Different sample types require specific methodological considerations:

When working with FFPE tissues, research has shown that phospho-protein detection maintains significant correlation with clinical markers despite the fixation process. Nevertheless, quantitative comparisons between FFPE and fresh samples should be approached with caution due to potential differences in epitope accessibility .

How should quantitative data from Phospho-PXN (Tyr88) antibody experiments be normalized and statistically analyzed?

For robust quantitative analysis of phospho-paxillin data:

• Normalization strategies:

  • For Western blot: Normalize phospho-signal to total paxillin expression using a pan-paxillin antibody on stripped membranes or parallel blots

  • For mass spectrometry: Apply stable isotope dimethyl labeling prior to immunoaffinity purification for reliable quantification

  • For immunohistochemistry: Use digital image analysis with internal control tissues on each slide

• Statistical considerations:

  • Account for non-normal distribution of phosphorylation data (often right-skewed)

  • Apply appropriate transformations (log, square root) before parametric testing if needed

  • Use non-parametric tests when assumptions for parametric testing cannot be met

  • Implement multiple testing corrections for large-scale phosphoproteomic datasets

  • Consider biological replicates (n≥3) essential for meaningful statistical analysis

• Visualization approaches:

  • Present data as fold-change relative to control conditions

  • For time-course experiments, plot normalized phosphorylation levels against time

  • Use heatmaps for displaying patterns across multiple phosphorylation sites or conditions

Following these guidelines ensures proper interpretation of phosphorylation data within the appropriate biological context.

What are the common pitfalls in interpreting phosphorylation status data obtained using Phospho-PXN (Tyr88) antibody?

When interpreting phospho-paxillin data, researchers should be aware of these common pitfalls:

• Confounding phosphorylation sites: Paxillin contains multiple phosphorylation sites (Y31, Y40, Y88, Y118). Changes in one site may not reflect changes at other sites, necessitating site-specific antibodies for comprehensive analysis.

• Context-dependent significance: The same phosphorylation event may have different functional outcomes depending on cell type, tissue context, or disease state.

• Temporal dynamics oversimplification: Single time-point measurements may miss important dynamic changes in phosphorylation status.

• Causal relationship assumptions: Correlation between paxillin phosphorylation and cellular phenotypes does not necessarily imply causation.

• Technical artifacts:

  • Loss of phosphorylation during sample processing

  • Non-specific antibody binding

  • Quantification challenges in saturated signals

• Biological variability interpretation: Distinguishing biologically meaningful changes from normal variation requires appropriate statistical analysis and sufficient replication.

• Cross-talk with other post-translational modifications: Phosphorylation at Tyr88 may influence or be influenced by other modifications on paxillin (e.g., serine phosphorylation, ubiquitination) .

How can Phospho-PXN (Tyr88) antibody be integrated into multiplexed phosphoprotein detection systems?

Emerging multiplexed approaches offer powerful new capabilities:

• Reverse Phase Protein Array (RPPA):

  • High-throughput screening of hundreds of samples simultaneously

  • Compatible with alkaline phosphatase (AP) treatment for phospho-antibody validation

  • Demonstrated reproducibility and specificity in clinical specimens

  • Suitable for both fresh frozen and FFPE tissue samples

  • Enables correlation with clinical features and pathological markers

• Mass spectrometry integration:

  • Immunoaffinity enrichment using Phospho-PXN (Tyr88) antibody prior to MS analysis

  • Combined with stable isotope labeling for quantitative comparisons

  • Allows identification of co-regulated phosphorylation events

  • Can identify up to 80% phosphotyrosine peptides from ~4mg starting material

• Multiplex immunofluorescence:

  • Sequential staining with multiple phospho-specific antibodies

  • Tyramide signal amplification for enhanced sensitivity

  • Spectral unmixing to resolve overlapping fluorophores

  • Spatial context preservation for analyzing phosphorylation in distinct cellular compartments

These integrated approaches enable comprehensive phosphoproteomic profiling that places paxillin Tyr88 phosphorylation within broader signaling networks.

What is the current understanding of the relationship between paxillin Tyr88 phosphorylation and other tyrosine phosphorylation sites on paxillin?

The complex interplay between multiple phosphorylation sites includes:

• Hierarchical phosphorylation patterns:

  • Evidence suggests specific temporal ordering of phosphorylation events

  • Phosphorylation at one site may enhance or inhibit modification at other sites

  • Tyr88 phosphorylation may influence subsequent phosphorylation at Tyr31, Tyr40, or Tyr118

• Site-specific signaling consequences:

  • Different phosphorylation sites create binding sites for distinct SH2 domain-containing proteins

  • This results in recruitment of unique downstream effectors

  • Combinatorial phosphorylation patterns may function as a molecular code determining specific cellular outcomes

• Kinase specificity and regulation:

  • Different kinases (e.g., SRC, FAK) may preferentially target specific tyrosine residues

  • Phosphorylation at Tyr88 may result from distinct upstream signaling events compared to other sites

  • Quantitative mass spectrometry studies have begun mapping these differential regulation patterns

• Coordinated dephosphorylation mechanisms:

  • Phosphatases may show preferences for specific phosphorylated residues

  • Temporal regulation of dephosphorylation contributes to signaling specificity

Understanding this interplay requires comprehensive phosphoproteomic approaches that examine all phosphorylation sites simultaneously under various cellular conditions.